Your request to link to rcsb for Cyclin-A2/Cyclin-dependent%20kinase%202

• 1CKP: human cyclin dependent kinase 2 complexed with the inhibitor purvalanol b (10.1126/SCIENCE.281.5376.533 )
• 1DI8: the structure of cyclin-dependent kinase 2 (cdk2) in complex with 4-[3-hydroxyanilino]-6,7-dimethoxyquinazoline (10.1021/JM990401T )
• 1DM2: human cyclin-dependent kinase 2 complexed with the inhibitor hymenialdisine (10.1016/S1074-5521(00)00063-6 )
• 1E1V: human cyclin dependent kinase 2 complexed with the inhibitor nu2058 (10.1021/JM990628O )
• 1E1X: human cyclin dependent kinase 2 complexed with the inhibitor nu6027 (10.1021/JM990628O )
• 1E9H: thr 160 phosphorylated cdk2 - human cyclin a3 complex with the inhibitor indirubin-5-sulphonate bound (10.1016/S0969-2126(01)00598-6 )
• 1F5Q: crystal structure of murine gamma herpesvirus cyclin complexed to human cyclin dependent kinase 2 (10.1093/EMBOJ/19.12.2877 )
• 1FIN: cyclin a-cyclin-dependent kinase 2 complex (10.1038/376313A0 )
• 1FQ1: crystal structure of kinase associated phosphatase (kap) in complex with phospho-cdk2 (10.1016/S1097-2765(01)00208-8 )
• 1FVT: the structure of cyclin-dependent kinase 2 (cdk2) in complex with an oxindole inhibitor (10.1126/SCIENCE.291.5501.134 )
• 1FVV: the structure of cdk2/cyclin a in complex with an oxindole inhibitor (10.1126/SCIENCE.291.5501.134 )
• 1G5S: crystal structure of human cyclin dependent kinase 2 (cdk2) in complex with the inhibitor h717 (10.1021/JM001043T )
• 1GIH: human cyclin dependent kinase 2 complexed with the cdk4 inhibitor (10.1074/JBC.M102060200 )
• 1GII: human cyclin dependent kinase 2 complexed with the cdk4 inhibitor (10.1074/JBC.M102060200 )
• 1GIJ: human cyclin dependent kinase 2 complexed with the cdk4 inhibitor (10.1074/JBC.M102060200 )
• 1GY3: pcdk2/cyclin a in complex with mgadp, nitrate and peptide substrate (10.1021/BI0201724 )
• 1GZ8: human cyclin dependent kinase 2 complexed with the inhibitor 2-amino- 6-(3'-methyl-2'-oxo)butoxypurine (10.1021/JM020056Z )
• 1H00: cdk2 in complex with a disubstituted 4, 6-bis anilino pyrimidine cdk4 inhibitor (10.1016/S0960-894X(03)00202-6 )
• 1H01: cdk2 in complex with a disubstituted 2, 4-bis anilino pyrimidine cdk4 inhibitor (10.1016/S0960-894X(03)00202-6 )
• 1H07: cdk2 in complex with a disubstituted 4, 6-bis anilino pyrimidine cdk4 inhibitor (10.1016/S0960-894X(03)00202-6 )
• 1H08: cdk2 in complex with a disubstituted 2, 4-bis anilino pyrimidine cdk4 inhibitor (10.1016/S0960-894X(03)00202-6 )
• 1H0V: human cyclin dependent protein kinase 2 in complex with the inhibitor 2-amino-6-[(r)-pyrrolidino-5'-yl]methoxypurine (10.1021/JM020056Z )
• 1H0W: human cyclin dependent protein kinase 2 in complex with the inhibitor 2-amino-6-[cyclohex-3-enyl]methoxypurine (10.1021/JM020056Z )
• 1H1P: structure of human thr160-phospho cdk2/cyclin a complexed with the inhibitor nu2058 (10.1038/NSB842 )
• 1H1Q: structure of human thr160-phospho cdk2/cyclin a complexed with the inhibitor nu6094 (10.1038/NSB842 )
• 1H1R: structure of human thr160-phospho cdk2/cyclin a complexed with the inhibitor nu6086 (10.1038/NSB842 )
• 1H1S: structure of human thr160-phospho cdk2/cyclin a complexed with the inhibitor nu6102 (10.1038/NSB842 )
• 1H24: cdk2/cyclin a in complex with a 9 residue recruitment peptide from e2f (10.1021/BI0268910 )
• 1H25: cdk2/cyclin a in complex with an 11-residue recruitment peptide from retinoblastoma-associated protein (10.1021/BI0268910 )
• 1H26: cdk2/cyclin a in complex with an 11-residue recruitment peptide from p53 (10.1021/BI0268910 )
• 1H27: cdk2/cyclin a in complex with an 11-residue recruitment peptide from p27 (10.1021/BI0268910 )
• 1H28: cdk2/cyclin a in complex with an 11-residue recruitment peptide from p107 (10.1021/BI0268910 )
• 1HCK: human cyclin-dependent kinase 2 (10.1021/JM960402A )
• 1HCL: human cyclin-dependent kinase 2 (10.1021/JM960402A )
• 1JST: phosphorylated cyclin-dependent kinase-2 bound to cyclin a (10.1038/NSB0896-696 )
• 1JSU: p27(kip1)/cyclin a/cdk2 complex (10.1038/382325A0 )
• 1JSV: the structure of cyclin-dependent kinase 2 (cdk2) in complex with 4- [(6-amino-4-pyrimidinyl)amino]benzenesulfonamide
• 1JVP: crystal structure of human cdk2 (unphosphorylated) in complex with pkf049-365 (10.1016/S0960-894X(01)00715-6 )
• 1KE5: cdk2 complexed with n-methyl-4-{[(2-oxo-1,2-dihydro-3h-indol-3- ylidene)methyl]amino}benzenesulfonamide (10.1021/JM010117D )
• 1KE6: cyclin-dependent kinase 2 (cdk2) complexed with n-methyl-{4-[2-(7-oxo- 6,7-dihydro-8h-[1,3]thiazolo[5,4-e]indol-8-ylidene) hydrazino]phenyl}methanesulfonamide (10.1021/JM010117D )
• 1KE7: cyclin-dependent kinase 2 (cdk2) complexed with 3-{[(2,2-dioxido-1,3- dihydro-2-benzothien-5-yl)amino]methylene}-5-(1,3-oxazol-5-yl)-1,3- dihydro-2h-indol-2-one (10.1021/JM010117D )
• 1KE8: cyclin-dependent kinase 2 (cdk2) complexed with 4-{[(2-oxo-1,2- dihydro-3h-indol-3-ylidene)methyl]amino}-n-(1,3-thiazol-2-yl) benzenesulfonamide (10.1021/JM010117D )
• 1KE9: cyclin-dependent kinase 2 (cdk2) complexed with 3-{[4-({[amino(imino) methyl]aminosulfonyl)anilino]methylene}-2-oxo-2,3-dihydro-1h-indole (10.1021/JM010117D )
• 1OGU: structure of human thr160-phospho cdk2/cyclin a complexed with a 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitor (10.1016/S0960-894X(03)00651-6 )
• 1OI9: structure of human thr160-phospho cdk2/cyclin a complexed with a 6-cyclohexylmethyloxy-2-anilino-purine inhibitor (10.1021/JM0311442 )
• 1OIQ: imidazopyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation (10.1016/S0960-894X(03)00638-3 )
• 1OIR: imidazopyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation (10.1016/S0960-894X(03)00638-3 )
• 1OIT: imidazopyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation (10.1016/S0960-894X(03)00638-3 )
• 1OIU: structure of human thr160-phospho cdk2/cyclin a complexed with a 6-cyclohexylmethyloxy-2-anilino-purine inhibitor (10.1021/JM0311442 )
• 1OIY: structure of human thr160-phospho cdk2/cyclin a complexed with a 6-cyclohexylmethyloxy-2-anilino-purine inhibitor (10.1021/JM0311442 )
• 1OKV: cyclin a binding groove inhibitor h-arg-arg-leu-ile-phe-nh2 (10.1016/J.STR.2003.11.006 )
• 1OKW: cyclin a binding groove inhibitor ac-arg-arg-leu-asn-(m-cl-phe)-nh2 (10.1016/J.STR.2003.11.006 )
• 1OL1: cyclin a binding groove inhibitor h-cit-cit-leu-ile-(p-f-phe)-nh2 (10.1016/J.STR.2003.11.006 )
• 1OL2: cyclin a binding groove inhibitor h-arg-arg-leu-asn-(p-f-phe)-nh2 (10.1016/J.STR.2003.11.006 )
• 1P2A: the structure of cyclin dependent kinase 2 (ckd2) with a trisubstituted naphthostyril inhibitor (10.1016/S0960-894X(03)00488-8 )
• 1P5E: the structure of phospho-cdk2/cyclin a in complex with the inhibitor 4,5,6,7-tetrabromobenzotriazole (tbs) (10.1046/J.1432-1033.2003.03697.X )
• 1PF8: crystal structure of human cyclin-dependent kinase 2 complexed with a nucleoside inhibitor (10.1016/J.BBRC.2003.09.114 )
• 1PKD: the crystal structure of ucn-01 in complex with phospho-cdk2/cyclin a
• 1PW2: apo structure of human cyclin-dependent kinase 2 (10.1016/S0969-2126(03)00060-1 )
• 1PXI: human cyclin dependent kinase 2 complexed with the inhibitor 4-(2,5-dichloro-thiophen-3-yl)-pyrimidin-2- ylamine (10.1016/S0969-2126(03)00060-1 )
• 1PXJ: human cyclin dependent kinase 2 complexed with the inhibitor 4-(2,4-dimethyl-thiazol-5-yl)-pyrimidin-2-ylamine (10.1016/S0969-2126(03)00060-1 )
• 1PXK: human cyclin dependent kinase 2 complexed with the inhibitor n-[4-(2,4-dimethyl-thiazol-5-yl)pyrimidin-2-yl]- n'-hydroxyiminoformamide (10.1016/S0969-2126(03)00060-1 )
• 1PXL: human cyclin dependent kinase 2 complexed with the inhibitor [4-(2,4-dimethyl-thiazol-5-yl)-pyrimidin-2-yl]- (4-trifluoromethyl-phenyl)-amine (10.1016/S0969-2126(03)00060-1 )
• 1PXM: human cyclin dependent kinase 2 complexed with the inhibitor 3-[4-(2,4-dimethyl-thiazol-5-yl)-pyrimidin-2- ylamino]-phenol (10.1021/JM0309957 )
• 1PXN: human cyclin dependent kinase 2 complexed with the inhibitor 4-[4-(4-methyl-2-methylamino-thiazol-5-yl)- pyrimidin-2-ylamino]-phenol (10.1021/JM0309957 )
• 1PXO: human cyclin dependent kinase 2 complexed with the inhibitor [4-(2-amino-4-methyl-thiazol-5-yl)-pyrimidin-2- yl]-(3-nitro-phenyl)-amine (10.1021/JM0309957 )
• 1PXP: human cyclin dependent kinase 2 complexed with the inhibitor n-[4-(2,4-dimethyl-thiazol-5-yl)-pyrimidin-2-yl]- n',n'-dimethyl-benzene-1,4-diamine (10.1021/JM0309957 )
• 1PYE: crystal structure of cdk2 with inhibitor
• 1QMZ: phosphorylated cdk2-cyclyin a-substrate peptide complex (10.1038/15674 )
• 1R78: cdk2 complex with a 4-alkynyl oxindole inhibitor (10.1016/J.BMCL.2003.12.009 )
• 1URC: cyclin a binding groove inhibitor ace-arg-lys-leu-phe-gly (10.1039/B409157D )
• 1URW: cdk2 in complex with an imidazo[1,2-b]pyridazine (10.1016/J.BMCL.2004.02.008 )
• 1V1K: cdk2 in complex with a disubstituted 4, 6-bis anilino pyrimidine cdk4 inhibitor (10.1016/S0960-894X(03)00202-6 )
• 1VIN: bovine cyclin a3 (10.1016/S0969-2126(01)00259-3 )
• 1VYW: structure of cdk2/cyclin a with pnu-292137 (10.1021/JM031145U )
• 1VYZ: structure of cdk2 complexed with pnu-181227 (10.1021/JM031145U )
• 1W0X: crystal structure of human cdk2 in complex with the inhibitor olomoucine. (10.1002/PROT.340220408 )
• 1W8C: co-crystal structure of 6-cyclohexylmethoxy-8-isopropyl-9h-purin-2- ylamine and monomeric cdk2 (10.1021/JM401555V )
• 1W98: the structural basis of cdk2 activation by cyclin e (10.1038/SJ.EMBOJ.7600554 )
• 1WCC: screening for fragment binding by x-ray crystallography (10.1021/JM0495778 )
• 1Y8Y: crystal structure of human cdk2 complexed with a pyrazolo[1, 5-a]pyrimidine inhibitor (10.1016/J.BMCL.2004.12.073 )
• 1Y91: crystal structure of human cdk2 complexed with a pyrazolo[1, 5-a]pyrimidine inhibitor (10.1016/J.BMCL.2004.12.073 )
• 1YKR: crystal structure of cdk2 with an aminoimidazo pyridine inhibitor (10.1016/J.BMCL.2005.01.052 )
• 2A0C: human cdk2 in complex with olomoucine ii, a novel 2,6,9- trisubstituted purine cyclin-dependent kinase inhibitor (10.1007/S00018-005-5185-1 )
• 2A4L: human cyclin-dependent kinase 2 in complex with roscovitine (10.1111/J.1432-1033.1997.0518A.X )
• 2B52: human cyclin dependent kinase 2 (cdk2) complexed with dph- 042562 (10.1016/J.BMCL.2003.11.008 )
• 2B53: human cyclin dependent kinase 2 (cdk2) complexed with din- 234325 (10.1016/S0960-894X(01)00185-8 )
• 2B54: human cyclin dependent kinase 2 (ckd2)complexed with din- 232305 (10.1021/JM020455U )
• 2B55: human cyclin dependent kinase 2 (cdk2) complexed with indenopyraxole din-101312 (10.1021/JM0201722 )
• 2BHE: human cyclin dependent protein kinase 2 in complex with the inhibitor 5-bromo-indirubine (10.1002/CBIC.200400108 )
• 2BHH: human cyclin dependent protein kinase 2 in complex with the inhibitor 4-hydroxypiperindinesulfonyl-indirubine (10.1002/CBIC.200400108 )
• 2BKZ: structure of cdk2-cyclin a with pha-404611 (10.1016/J.BMCL.2005.01.023 )
• 2BPM: structure of cdk2-cyclin a with pha-630529 (10.1021/JM0408870 )
• 2BTR: structure of cdk2 complexed with pnu-198873 (10.1016/J.JMGM.2005.09.012 )
• 2BTS: structure of cdk2 complexed with pnu-230032 (10.1016/J.JMGM.2005.09.012 )
• 2C4G: structure of cdk2-cyclin a with pha-533514 (10.1016/J.BMCL.2005.10.071 )
• 2C5N: differential binding of inhibitors to active and inactive cdk2 provides insights for drug design (10.1016/J.CHEMBIOL.2005.11.011 )
• 2C5O: differential binding of inhibitors to active and inactive cdk2 provides insights for drug design (10.1016/J.CHEMBIOL.2005.11.011 )
• 2C5V: differential binding of inhibitors to active and inactive cdk2 provides insights for drug design (10.1016/J.CHEMBIOL.2005.11.011 )
• 2C5X: differential binding of inhibitors to active and inactive cdk2 provides insights for drug design (10.1016/J.CHEMBIOL.2005.11.011 )
• 2C5Y: differential binding of inhibitors to active and inactive cdk2 provides insights for drug design (10.1016/J.CHEMBIOL.2005.11.011 )
• 2C68: crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor (10.1016/J.BMCL.2005.11.048 )
• 2C69: crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor (10.1016/J.BMCL.2005.11.048 )
• 2C6I: crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor (10.1016/J.BMCL.2005.11.048 )
• 2C6K: crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor (10.1016/J.BMCL.2005.11.048 )
• 2C6L: crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor (10.1016/J.BMCL.2005.11.048 )
• 2C6M: crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor (10.1016/J.BMCL.2005.11.048 )
• 2C6O: crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor (10.1016/J.BMCL.2005.11.048 )
• 2C6T: crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor (10.1016/J.BMCL.2005.11.048 )
• 2CCH: the crystal structure of cdk2 cyclin a in complex with a substrate peptide derived from cdc modified with a gamma-linked atp analogue (10.1074/JBC.M600480200 )
• 2CCI: crystal structure of phospho-cdk2 cyclin a in complex with a peptide containing both the substrate and recruitment sites of cdc6 (10.1074/JBC.M600480200 )
• 2CJM: mechanism of cdk inhibition by active site phosphorylation: cdk2 y15p t160p in complex with cyclin a structure (10.1074/JBC.M609151200 )
• 2CLX: 4-arylazo-3,5-diamino-1h-pyrazole cdk inhibitors: sar study, crystal structure in complex with cdk2, selectivity, and cellular effects (10.1021/JM0605740 )
• 2DS1: human cyclin dependent kinase 2 complexed with the cdk4 inhibitor (10.1016/J.BMCL.2006.07.026 )
• 2DUV: structure of cdk2 with a 3-hydroxychromones (10.1016/J.BMCL.2006.12.011 )
• 2EXM: human cdk2 in complex with isopentenyladenine (10.1002/PROT.340220408 )
• 2FVD: cyclin dependent kinase 2 (cdk2) with diaminopyrimidine inhibitor (10.1021/JM0606138 )
• 2G9X: structure of thr 160 phosphorylated cdk2/cyclin a in complex with the inhibitor nu6271 (10.1021/JA060595J )
• 2I40: cdk2/cyclin a complexed with a thiophene carboxamide inhibitor (10.1016/J.BMCL.2006.09.018 )
• 2IW6: structure of human thr160-phospho cdk2-cyclin a complexed with a bisanilinopyrimidine inhibitor (10.1021/JM060216X )
• 2IW8: structure of human thr160-phospho cdk2-cyclin a f82h-l83v- h84d mutant with an o6-cyclohexylmethylguanine inhibitor (10.1021/JM060216X )
• 2IW9: structure of human thr160-phospho cdk2-cyclin a complexed with a bisanilinopyrimidine inhibitor (10.1021/JM060216X )
• 2J9M: crystal structure of cdk2 in complex with macrocyclic aminopyrimidine (10.1002/CMDC.200600199 )
• 2JGZ: crystal structure of phospho-cdk2 in complex with cyclin b (10.4161/CC.6.11.4278 )
• 2R3F: crystal structure of cyclin-dependent kinase 2 with inhibitor (10.1002/BIP.20868 )
• 2R3G: crystal structure of cyclin-dependent kinase 2 with inhibitor (10.1002/BIP.20868 )
• 2R3H: crystal structure of cyclin-dependent kinase 2 with inhibitor (10.1002/BIP.20868 )
• 2R3I: crystal structure of cyclin-dependent kinase 2 with inhibitor (10.1002/BIP.20868 )
• 2R3J: crystal structure of cyclin-dependent kinase 2 with inhibitor (10.1002/BIP.20868 )
• 2R3K: crystal structure of cyclin-dependent kinase 2 with inhibitor (10.1002/BIP.20868 )
• 2R3L: crystal structure of cyclin-dependent kinase 2 with inhibitor (10.1002/BIP.20868 )
• 2R3M: crystal structure of cyclin-dependent kinase 2 with inhibitor (10.1002/BIP.20868 )
• 2R3N: crystal structure of cyclin-dependent kinase 2 with inhibitor (10.1002/BIP.20868 )
• 2R3O: crystal structure of cyclin-dependent kinase 2 with inhibitor (10.1002/BIP.20868 )
• 2R3P: crystal structure of cyclin-dependent kinase 2 with inhibitor (10.1002/BIP.20868 )
• 2R3Q: crystal structure of cyclin-dependent kinase 2 with inhibitor (10.1002/BIP.20868 )
• 2R3R: crystal structure of cyclin-dependent kinase 2 with inhibitor (10.1002/BIP.20868 )
• 2R64: crystal structure of a 3-aminoindazole compound with cdk2 (10.1016/J.BMCL.2008.03.002 )
• 2UUE: replace: a strategy for iterative design of cyclin binding groove inhibitors (10.1002/CBIC.200600189 )
• 2UZB: crystal structure of human cdk2 complexed with a thiazolidinone inhibitor (10.1016/J.BMCL.2007.04.110 )
• 2UZD: crystal structure of human cdk2 complexed with a thiazolidinone inhibitor (10.1016/J.BMCL.2007.04.110 )
• 2UZE: crystal structure of human cdk2 complexed with a thiazolidinone inhibitor (10.1016/J.BMCL.2007.04.110 )
• 2UZL: crystal structure of human cdk2 complexed with a thiazolidinone inhibitor (10.1016/J.BMCL.2007.04.110 )
• 2UZN: crystal structure of human cdk2 complexed with a thiazolidinone inhibitor (10.1016/J.BMCL.2007.04.110 )
• 2UZO: crystal structure of human cdk2 complexed with a thiazolidinone inhibitor (10.1016/J.BMCL.2007.04.110 )
• 2V0D: crystal structure of human cdk2 complexed with a thiazolidinone inhibitor (10.1016/J.BMCL.2007.04.110 )
• 2V22: replace: a strategy for iterative design of cyclin binding groove inhibitors (10.1002/CBIC.200600189 )
• 2VTA: identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design. (10.1021/JM800382H )
• 2VTH: identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design (10.1021/JM800382H )
• 2VTI: identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design. (10.1021/JM800382H )
• 2VTJ: identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design 13-jun-18 2vtj 1 title (10.1021/JM800382H )
• 2VTL: identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design 13-jun-18 2vtl 1 title (10.1021/JM800382H )
• 2VTM: identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design. (10.1021/JM800382H )
• 2VTN: identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design. (10.1021/JM800382H )
• 2VTO: identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design. (10.1021/JM800382H )
• 2VTP: identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design. (10.1021/JM800382H )
• 2VTQ: identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design. (10.1021/JM800382H )
• 2VTR: identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design 13-jun-18 2vtr 1 title (10.1021/JM800382H )
• 2VTS: identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design. (10.1021/JM800382H )
• 2VTT: identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design. (10.1021/JM800382H )
• 2VU3: identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design. (10.1021/JM800382H )
• 2VV9: cdk2 in complex with an imidazole piperazine (10.1016/J.BMCL.2008.06.027 )
• 2W05: structure of cdk2 in complex with an imidazolyl pyrimidine, compound 5b (10.1016/J.BMCL.2008.09.024 )
• 2W06: structure of cdk2 in complex with an imidazolyl pyrimidine, compound 5c (10.1016/J.BMCL.2008.09.024 )
• 2W17: cdk2 in complex with the imidazole pyrimidine amide, compound (s)-8b (10.1016/J.BMCL.2008.10.102 )
• 2W1H: fragment-based discovery of the pyrazol-4-yl urea (at9283), a multi-targeted kinase inhibitor with potent aurora kinase activity (10.1021/JM800984V )
• 2WEV: truncation and optimisation of peptide inhibitors of cdk2, cyclin a through structure guided design (10.1002/CMDC.200900093 )
• 2WFY: truncation and optimisation of peptide inhibitors of cdk2, cyclin a through structure guided design (10.1002/CMDC.200900093 )
• 2WHB: truncation and optimisation of peptide inhibitors of cdk2, cyclin a through structure guided design (10.1002/CMDC.200900093 )
• 2WIH: structure of cdk2-cyclin a with pha-848125 (10.1021/JM9006559 )
• 2WIP: structure of cdk2-cyclin a complexed with 8-anilino-1-methyl-4,5- dihydro- 1h-pyrazolo[4,3-h] quinazoline-3-carboxylic acid (10.1021/JM9006559 )
• 2WMA: structural and thermodynamic consequences of cyclization of peptide ligands for the recruitment site of cyclin a
• 2WMB: structural and thermodynamic consequences of cyclization of peptide ligands for the recruitment site of cyclin a
• 2WPA: optimisation of 6,6-dimethyl pyrrolo 3,4-c pyrazoles: identification of pha-793887, a potent cdk inhibitor suitable for intravenous dosing (10.1016/J.BMC.2010.01.042 )
• 2WXV: structure of cdk2-cyclin a with a pyrazolo(4,3-h) quinazoline-3- carboxamide inhibitor (10.1021/JM901710H )
• 2X1N: truncation and optimisation of peptide inhibitors of cdk2, cyclin a through structure guided design (10.1021/JM901660C )
• 2XMY: discovery and characterisation of 2-anilino-4-(thiazol-5-yl) pyrimidine transcriptional cdk inhibitors as anticancer agents (10.1016/J.CHEMBIOL.2010.07.016 )
• 2XNB: discovery and characterisation of 2-anilino-4-(thiazol-5-yl) pyrimidine transcriptional cdk inhibitors as anticancer agents (10.1016/J.CHEMBIOL.2010.07.016 )
• 3BHT: structure of phosphorylated thr160 cdk2/cyclin a in complex with the inhibitor meriolin 3 (10.1158/0008-5472.CAN-07-1826 )
• 3BHU: structure of phosphorylated thr160 cdk2/cyclin a in complex with the inhibitor meriolin 5 (10.1158/0008-5472.CAN-07-1826 )
• 3BHV: structure of phosphorylated thr160 cdk2/cyclin a in complex with the inhibitor variolin b (10.1158/0008-5472.CAN-07-1826 )
• 3DDP: structure of phosphorylated thr160 cdk2/cyclin a in complex with the inhibitor cr8 (10.1038/ONC.2008.191 )
• 3DDQ: structure of phosphorylated thr160 cdk2/cyclin a in complex with the inhibitor roscovitine (10.1038/ONC.2008.191 )
• 3DOG: structure of thr 160 phosphorylated cdk2/cyclin a in complex with the inhibitor n-&-n1 (10.1158/1535-7163.MCT-08-0080 )
• 3EID: cdk2/cyclina complexed with a pyrazolopyridazine inhibitor (10.1016/J.BMCL.2008.09.069 )
• 3EJ1: cdk2/cyclina complexed with a pyrazolopyridazine inhibitor (10.1016/J.BMCL.2008.09.069 )
• 3EOC: cdk2/cyclina complexed with a imidazo triazin-2-amine (10.1016/J.BMCL.2008.09.100 )
• 3EZR: cdk-2 with indazole inhibitor 17 bound at its active site (10.1016/J.BMCL.2008.11.105 )
• 3EZV: cdk-2 with indazole inhibitor 9 bound at its active site (10.1016/J.BMCL.2008.11.105 )
• 3F5X: cdk-2-cyclin complex with indazole inhibitor 9 bound at its active site (10.1016/J.BMCL.2008.11.105 )
• 3FZ1: crystal structure of a benzthiophene inhibitor bound to human cyclin- dependent kinase-2 (cdk-2) (10.1016/J.BMCL.2009.02.017 )
• 3IG7: novel cdk-5 inhibitors - crystal structure of inhibitor efp with cdk-2 (10.1016/J.BMCL.2009.08.019 )
• 3IGG: novel cdk-5 inhibitors - crystal structure of inhibitor efq with cdk-2 (10.1016/J.BMCL.2009.08.019 )
• 3LE6: the structure of cyclin dependent kinase 2 (ckd2) with a pyrazolobenzodiazepine inhibitor (10.1016/J.BMCL.2010.08.079 )
• 3LFN: crystal structure of cdk2 with sar57, an aminoindazole type inhibitor (10.1016/J.BMCL.2010.01.114 )
• 3LFQ: crystal structure of cdk2 with sar60, an aminoindazole type inhibitor (10.1016/J.BMCL.2010.01.114 )
• 3LFS: crystal structure of cdk2 with sar37, an aminoindazole type inhibitor (10.1016/J.BMCL.2010.01.114 )
• 3MY5: cdk2/cyclina in complex with drb (10.1016/J.CHEMBIOL.2010.07.012 )
• 3NS9: crystal structure of cdk2 in complex with inhibitor bs-194 (10.1021/JM100732T )
• 3PJ8: structure of cdk2 in complex with a pyrazolo[4,3-d]pyrimidine bioisostere of roscovitine. (10.1021/JM200064P )
• 3PXF: cdk2 in complex with two molecules of 8-anilino-1-naphthalene sulfonate (10.1021/CB100410M )
• 3PXQ: cdk2 in complex with 3 molecules of 8-anilino-1-naphthalene sulfonate (10.1021/CB100410M )
• 3PXR: apo cdk2 crystallized from jeffamine (10.1021/CB100410M )
• 3PXY: cdk2 in complex with inhibitor jws648 (10.1021/CB100410M )
• 3PXZ: cdk2 ternary complex with jws648 and ans (10.1021/CB100410M )
• 3PY0: cdk2 in complex with inhibitor su9516 (10.1021/CB100410M )
• 3PY1: cdk2 ternary complex with su9516 and ans (10.1021/CB100410M )
• 3QHR: structure of a pcdk2/cyclina transition-state mimic (10.1016/J.STR.2011.02.016 )
• 3QHW: structure of a pcdk2/cyclina transition-state mimic (10.1016/J.STR.2011.02.016 )
• 3QL8: cdk2 in complex with inhibitor jws-6-260
• 3QQF: cdk2 in complex with inhibitor l1
• 3QQG: cdk2 in complex with inhibitor l2-5
• 3QQH: cdk2 in complex with inhibitor l2-2
• 3QQJ: cdk2 in complex with inhibitor l2
• 3QQK: cdk2 in complex with inhibitor l4 (10.1021/JM301234K )
• 3QQL: cdk2 in complex with inhibitor l3
• 3QRT: cdk2 in complex with inhibitor nsk-mc2-55
• 3QRU: cdk2 in complex with inhibitor nsk-mc1-12
• 3QTQ: cdk2 in complex with inhibitor rc-1-137 (10.1021/JM301234K )
• 3QTR: cdk2 in complex with inhibitor rc-1-148 (10.1021/JM301234K )
• 3QTS: cdk2 in complex with inhibitor rc-2-12 (10.1021/JM301234K )
• 3QTU: cdk2 in complex with inhibitor rc-2-132 (10.1021/JM301234K )
• 3QTW: cdk2 in complex with inhibitor rc-2-13 (10.1021/JM301234K )
• 3QTX: cdk2 in complex with inhibitor rc-2-35 (10.1021/JM301234K )
• 3QTZ: cdk2 in complex with inhibitor rc-2-36 (10.1021/JM301234K )
• 3QU0: cdk2 in complex with inhibitor rc-2-38 (10.1021/JM301234K )
• 3QWJ: cdk2 in complex with inhibitor kvr-1-142
• 3QWK: cdk2 in complex with inhibitor kvr-1-150
• 3QX2: cdk2 in complex with inhibitor kvr-1-190
• 3QX4: cdk2 in complex with inhibitor kvr-1-78
• 3QXO: cdk2 in complex with inhibitor kvr-1-84
• 3QXP: cdk2 in complex with inhibitor rc-3-89 (10.1021/JM301234K )
• 3QZF: cdk2 in complex with inhibitor jws-6-52
• 3QZG: cdk2 in complex with inhibitor jws-6-76
• 3QZH: cdk2 in complex with inhibitor kvr-1-124
• 3QZI: cdk2 in complex with inhibitor kvr-1-126
• 3R1Q: cdk2 in complex with inhibitor kvr-1-102
• 3R1S: cdk2 in complex with inhibitor kvr-1-127
• 3R1Y: cdk2 in complex with inhibitor kvr-1-134
• 3R28: cdk2 in complex with inhibitor kvr-1-140
• 3R6X: cdk2 in complex with inhibitor kvr-1-158
• 3R71: cdk2 in complex with inhibitor kvr-1-162
• 3R73: cdk2 in complex with inhibitor kvr-1-164
• 3R7E: cdk2 in complex with inhibitor kvr-1-67
• 3R7I: cdk2 in complex with inhibitor kvr-1-74
• 3R7U: cdk2 in complex with inhibitor kvr-1-75
• 3R7V: cdk2 in complex with inhibitor kvr-1-9
• 3R7Y: cdk2 in complex with inhibitor kvr-2-88
• 3R83: cdk2 in complex with inhibitor kvr-2-92
• 3R8L: cdk2 in complex with inhibitor l3-4
• 3R8M: cdk2 in complex with inhibitor l3-3
• 3R8P: cdk2 in complex with inhibitor nsk-mc1-6
• 3R8U: cdk2 in complex with inhibitor rc-1-132 (10.1021/JM301234K )
• 3R8V: cdk2 in complex with inhibitor rc-1-135 (10.1021/JM301234K )
• 3R8Z: cdk2 in complex with inhibitor rc-1-136 (10.1021/JM301234K )
• 3R9D: cdk2 in complex with inhibitor rc-2-135 (10.1021/JM301234K )
• 3R9H: cdk2 in complex with inhibitor rc-2-142 (10.1021/JM301234K )
• 3R9N: cdk2 in complex with inhibitor rc-2-21 (10.1021/JM301234K )
• 3R9O: cdk2 in complex with inhibitor rc-2-143 (10.1021/JM301234K )
• 3RAH: cdk2 in complex with inhibitor rc-2-22 (10.1021/JM301234K )
• 3RAI: cdk2 in complex with inhibitor kvr-1-160
• 3RAK: cdk2 in complex with inhibitor rc-2-32 (10.1021/JM301234K )
• 3RAL: cdk2 in complex with inhibitor rc-2-34 (10.1021/JM301234K )
• 3RJC: cdk2 in complex with inhibitor l4-12 (10.1021/JM301234K )
• 3RK5: cdk2 in complex with inhibitor rc-2-72 (10.1021/JM301234K )
• 3RK7: cdk2 in complex with inhibitor rc-2-71 (10.1021/JM301234K )
• 3RK9: cdk2 in complex with inhibitor rc-2-74 (10.1021/JM301234K )
• 3RKB: cdk2 in complex with inhibitor rc-2-73 (10.1021/JM301234K )
• 3RM6: cdk2 in complex with inhibitor kvr-2-80
• 3RM7: cdk2 in complex with inhibitor kvr-1-91
• 3RMF: cdk2 in complex with inhibitor rc-2-33 (10.1021/JM301234K )
• 3RNI: cdk2 in complex with inhibitor rc-3-86 (10.1021/JM301234K )
• 3ROY: cdk2 in complex with inhibitor kvr-1-154
• 3RPO: cdk2 in complex with inhibitor kvr-1-156
• 3RPR: cdk2 in complex with inhibitor rc-2-49 (10.1021/JM301234K )
• 3RPV: cdk2 in complex with inhibitor rc-2-88 (10.1021/JM301234K )
• 3RPY: cdk2 in complex with inhibitor rc-2-40 (10.1021/JM301234K )
• 3RZB: cdk2 in complex with inhibitor rc-2-23 (10.1021/JM301234K )
• 3S00: cdk2 in complex with inhibitor l4-14 (10.1021/JM301234K )
• 3S0O: cdk2 in complex with inhibitor rc-1-138 (10.1021/JM301234K )
• 3S1H: cdk2 in complex with inhibitor rc-2-39 (10.1021/JM301234K )
• 3S2P: crystal structure of cdk2 with a 2-aminopyrimidine compound (10.1016/J.BMCL.2011.05.081 )
• 3SQQ: cdk2 in complex with inhibitor rc-3-96 (10.1021/JM301234K )
• 3SW4: crystal structure of the cdk2 in complex with thiazolylpyrimidine inhibitor
• 3SW7: crystal structure of the cdk2 in complex with thiazolylpyrimidine inhibitor
• 3TI1: cdk2 in complex with sunitinib (10.1002/CBIC.201200316 )
• 3TIY: cdk2 in complex with nsc 35676 (10.1002/CBIC.201200316 )
• 3TIZ: cdk2 in complex with nsc 111848 (10.1002/CBIC.201200316 )
• 3TNW: structure of cdk2/cyclin a in complex with can508 (10.1021/CB2004516 )
• 3ULI: human cyclin dependent kinase 2 (cdk2) bound to azabenzimidazole derivative (10.1016/J.BMCL.2012.01.018 )
• 3UNJ: cdk2 in complex with inhibitor yl1-038-31 (10.1021/CB200508B )
• 3UNK: cdk2 in complex with inhibitor yl5-083 (10.1021/CB200508B )
• 3WBL: crystal structure of cdk2 in complex with pyrazolopyrimidine inhibitor (10.1107/S0909049513020736 )
• 4ACM: cdk2 in complex with 3-amino-6-(4-{[2-(dimethylamino)ethyl]sulfamoyl}- phenyl)-n-pyridin-3-ylpyrazine-2-carboxamide (10.1021/JM201724M )
• 4BCK: structure of cdk2 in complex with cyclin a and a 2-amino-4- heteroaryl-pyrimidine inhibitor (10.1021/JM301495V )
• 4BCM: structure of cdk2 in complex with cyclin a and a 2-amino-4- heteroaryl-pyrimidine inhibitor (10.1021/JM301495V )
• 4BCN: structure of cdk2 in complex with cyclin a and a 2-amino-4- heteroaryl-pyrimidine inhibitor (10.1021/JM301495V )
• 4BCO: structure of cdk2 in complex with cyclin a and a 2-amino-4- heteroaryl-pyrimidine inhibitor (10.1021/JM301495V )
• 4BCP: structure of cdk2 in complex with cyclin a and a 2-amino-4- heteroaryl-pyrimidine inhibitor (10.1021/JM301475F )
• 4BCQ: structure of cdk2 in complex with cyclin a and a 2-amino-4- heteroaryl-pyrimidine inhibitor (10.1021/JM301495V )